CrossMark

ADRB3 polymorphism rs4994 (Trp64Arg) associates significantly with bodyweight elevation and dyslipidaemias in Saudis but not rs1801253 (Arg389Gly) polymorphism in ARDB1

Maha Daghestani[1], Mazin Daghestani[2], Mamoon Daghistani[3], Abdelmoneim Eldali[4], Zeinab K. Hassan[5], Maha H. Elamin[6] and Arjumand Warsy[7*] (ID)

Abstract

Background: In some populations, obesity and body weight related disorders show a correlation with polymorphisms in three subtypes of beta-adrenoceptor (β1, β2, and β3) [ADRB1, ADRB2 and ADRB3] genes. We scanned for the polymorphism of Arg389Gly (rs1801253) in ADRB1 and Trp64Arg (rs4994) in ADRB3 genes in Saudi population to determine association, if any, of these polymorphisms with obesity and related disorders.

Methods: We studied 329 non-related adults (33.1% men and 66.9% women), aged 18–36 years. Anthropometric measurements were recorded, and Body mass index (BMI) and waist/hip ratio were calculated; leptin, insulin, lipidogram, and glucose concentrations were determined. ADRB1 and ADRB3 polymorphisms (Arg389Gly and Trp64Arg, respectively) were screened by DNA sequencing. The subjects were divided into three groups according to BMI: normal weight (BMI < 25 kg/m^2), overweight (BMI ≥25.1–29.9 kg/m^2) subjects, and obese (≥30 kg/m^2).

Results: In the age-matched groups of the normal weight, overweight and obese male and female subjects, all anthropometric parameters were found to be significantly higher, and in the obese group, all biochemical parameters were significantly elevated compared to the normal weight controls. The allelic frequency of Gly389 ADRB1 did not differ amongst the three groups, whereas the frequency of Arg64 of ADRB3 gene was significantly higher in the overweight and obese subjects, compared with the normal weight subjects. In addition, subjects carrying Arg64 allele regardless of their BMI had a greater waist and hip circumference, W/H ratio, plasma cholesterol, triglyceride, LDL, leptin, insulin, and glucose level compared to those with the wild-type Trp allele.

Conclusion: The results of this study have shown a significant association between the Trp64Arg polymorphism in ADRB3 gene and the development of overweight and obesity in Saudi populations. It also has an influence on the levels of lipid, insulin, leptin, and glucose, whereas, Arg389Gly polymorphism in ADRB1 is not associated with overweight, obesity or dyslipidaemias in Saudis.

Keywords: β1 adrenoceptor, β3 adrenoceptor, Dyslipidaemias, Polymorphism, Obesity, Saudi population, χ^2 Chi square

* Correspondence: aswarsy@ksu.edu.sa
[7]Senior Scientist, Central Laboratory, Center for Scientific and Medical Female Colleges, King Saud University, P.O. Box 22455, Riyadh 11495, Saudi Arabia
Full list of author information is available at the end of the article

Daghestani *et al. Lipids in Health and Disease* (2018) 17:58

Page 2 of 9

Background

Obesity and diabetes mellitus Type 2 (T2DM) are rapidly growing public health problems in the Saudi population [1, 2]. A high risk of T2DM and cardiovascular complication is also associated with increased obesity [2, 3]. Several epidemiological and clinical studies have shown that human obesity is a multifactorial disorder, with both genetic predisposition and environmental factors contributing to its etiology [4, 5]. Extensive studies have linked different genetic loci to obesity, and strong linkage has between reported between beta (β) adrenoceptor polymorphisms (ADRB) and obesity or weight gain [6–10]. There are three subtypes of ARDB: β-1, β-2, and β-3, and these are involved in development, behavior, smooth muscle tone, heart function, and energy metabolism [11]. The three β -subtypes (β-1, β-2, and β-3) coexist in both white adipose tissue (WAT) and brown adipose tissue (BAT). In WAT, ADRB signaling is thought to stimulate lipolysis in response to fasting, whereas in BAT, it mediates heat production in response to cold exposure or overfeeding via activation of the uncoupling protein-1(UCP1) [12–14]. Catecholamines are regulators of lipolysis, and act via β1-, β2-, β3- (stimulatory), and α2- (inhibitory) adrenoceptor subtypes in adipose tissue. Most of the sympathetic nervous system-mediated energy expenditure in skeletal muscles takes place via the coupling of catecholamines with β2-adrenoceptors [15, 16] and plays important roles in energy expenditure and control of body weight [9–17]. Recently, it has been shown that *ARDBs* are polymorphic with single nucleotide polymorphism (SNPs) exerting functional consequences affecting receptor activity and regulation, and hence may contribute to the pathophysiology of obesity and related disorders [7–9]. Several studies have shown an association between *ADRB* polymorphism and BMI, T2DM, hypertension [HT] and dyslipidaemias, while other studies have failed to show such an association [18–53].

In our previous report, we have shown a link between obesity-related disorders in Saudi population and Gln27Glu polymorphism in *ARDB2* gene [9]. In the present study, we have investigated the relationship between polymorphism in *ARDB1* (rs1801253) and *ARDB3* (rs4994) genes and obesity and related disorders in the Saudi population.

Methods

Study group

The study was approved by the local ethics committee at the Umm Al Qura University, Makkah Al Mukaramah, Saudi Arabia (IRB No. 235). It included randomly chosen 329 unrelated Saudi subjects [men = 109 (33.1%) and women = 220 (66.9%)], from a nationwide population, with ages ranging from 18 to 36 years. Informed written consent was obtained from all study subjects before their participation.

Anthropometric and biochemical measurements

Anthropometric measurements included the recording of height, weight, waist and hip circumference by standard methods. Body mass index (BMI; kg/m^2) and waist-to-hip ratio (WHR) were calculated [54]. For biochemical studies, 20 ml of blood was drawn by venipuncture from an antecubital vein without compression, following an overnight fast, from each subject under study. 10 ml blood was placed in ethylenediaminetetraacetic acid (EDTA) coated tubes, 2 ml in tubes containing fluoride and the rest in plain tubes. All samples were immediately centrifuged at room temperature to collect the plasma/serum. Plasma glucose was determined in duplicate by a glucose-oxidase method adapted to an autoanalyzer (Hitachi 704, Boehringer Mannheim, Germany). Enzymatic methods using commercial kits (Boehringer Mannheim) were used to estimate total serum cholesterol, triglycerides, low-density lipoprotein [LDL] and high-density lipoprotein [HDL]. Plasma insulin and leptin concentrations were estimated by radioimmunoassay (RIA) using Human Insulin Specific RIA kit and Human Leptin RIA Kit, respectively (Linco Research, St Louis, MO).

Genotyping of *ADRB1* polymorphism (rs1801253)

The genomic DNAs of all the subjects were extracted from peripheral blood leukocytes using Gentra Systems Kit (Minneapolis, MN, cat # D5500). The DNA fragment containing codon 389 of the *ARDB1* gene was amplified by polymerase chain reaction (PCR) using a sense primer (5'-CTCTTCGTCTTCTTCAACTGGCT-3′) and an antisense primer (5'-CAACAAGGAACATCAGCAAGC-3′). The PCR conditions consisted of an initial denaturation step at 95 °C for 15 min, followed by 34 cycles of denaturation at 95 °C for 1 min, annealing at 60 °C for 1 min, and extension at 72 °C for 1 min, with a final extension of 10 min at 72 °C. With these primers, a PCR product was verified on 2% agarose gel electrophoresis. Nucleotide

Table 1 Anthropometric characteristics of control, overweight and obese study subjects

VARIABLES	Control (n = 115) mean ± SEM	Overweight (n = 68) mean ± SEM	Obese (n = 146) mean ± SEM	P value
Age (yr)	24.90 ± 0.44	25.56 ± 0.54	26.70 ± 0.43	0. 056
BMI (kg/m^2)	21.33 ± 0.19	26.93 ± 0.17	34.89 ± 0.50	0.0001
Waist (cm)	70.82 ± 0.79	85.13 ± 0.93	103.72 ± 1.23	0.0001
Hip (cm)	96.13 ± 0.68	102.22 ± 0.82	119.68 ± 1.15	0.0001
W/H Ratio	0.73 ± 0.006	0.84 ± 0.006	0.87 ± 0.006	0.0001

Values are mean ± SEM. Abbreviations: BMI, body mass index; W/H, waist/hip ratio; SEM: Standard Error of the Mean

Daghestani *et al. Lipids in Health and Disease* (2018) 17:58

Page 3 of 9

Table 2 Comparisons of clinical parameters amongst control, overweight and obese study subjects

VARIABLES	Control ($n = 115$) mean ± SEM	Overweight ($n = 68$) mean ± SEM	Obese ($n = 146$) mean ± SEM	P value
Cholesterol (mmol/L)	3.43 ± 0.04	4.19 ± 0.09	4.4 ± 0.07	0.0001
Triglyceride (mmol/L)	0.74 ± 0.02	1.082 ± 0.05	1.302 ± 0.04	0.0001
HDL (mmol/L)	1.32 ± 0.03	1.19 ± 0.04	1.07 ± 0.024	0.0001
LDL -cholesterol (mmol/L)	1.55 ± 0.05	2.07 ± 0.89	2.56 ± 0.06	0.0001
Leptin (ng/ml)	9.42 ± 0.48	17.51 ± 0.97	36.13 ± 1.67	0.0001
Fasting Insulin (pmol/L)	57.21 ± 2.09	72.23 ± 4.28	106.03 ± 3.07	0.0001
Fasting Glucose (mmol/L)	4.71 ± 0.041	5.051 ± 0.057	5.06 ± 0.05	0.0001

Values are mean ± SEM. *Abbreviations*: Values are mean ± SEM. *Abbreviations*: *HDL*: High-density lipoproteins; *LDL*: Low-density lipoprotein; *SE*: Standard Error of the Mean

sequencing was carried out by the ABI Big Dye Terminator protocol using ABI 3100 Avant Genetic Analyzer.

Genotyping of *ADRB3* polymorphism (rs4994)

The DNA fragment containing codon 64 of the *ADRB3* gene was amplified by PCR using a sense primer (5′-CCAGTGGGCTGCCAGGGG-3′) and an antisense primer (5′- GCCAGTGGCGCCCAACGG -3′). The PCR conditions were also the same as mentioned above for *ADRB1* studies. Nucleotide sequencing was carried out by the ABI Big Dye Terminator protocol using ABI 3100 Avant Genetic Analyzer.

Statistical analysis

Stat View program for Windows (version 8.0; SAS) was used to conduct all data analyses. Based on the value of BMI, the total population was grouped as normal weight (BMI < 25 kg/m^2), overweight (BMI ≥25.1–29.9 kg/m^2), and obese (≥30 kg/m^2). The data obtained was analyzed separately for each group and is presented as mean ± SEM. The comparisons of anthropometric parameters and biochemical and hormonal variables between overweight, obese and normal weight control subjects were carried out using the independent student's t-test and ANOVA.

The data were further grouped according to the three genotypes of *ARDB1* and *ARDB3* genes, and the anthropometric measurements, age, BMI, fasting serum insulin, leptin, glucose level and lipid profile, were compared by the Mann-Whitney U- test. To study the influence of the *ARDB1* and *ARDB3* genotypes on BMI, multivariable logistic regression was used. The different parameters were correlated using Pearson's correlation coefficient (r), and the *p*-value was obtained. Frequency distribution analysis was performed using the chi-square test, and frequencies of the different alleles in different groups (normal, overweight and obese) were compared. Relative risk was estimated by the odds ratios (ORs) and their 95% confidence intervals (CIs), and a p-value ≤0.05 was considered statistically significant.

Results

Obesity-related anthropometric and biochemical characteristics

Using a BMI cut-off point of BMI < 25 kg/m^2, BMI ≥ 25.1–29.9 kg/m^2) and BMI > 30 kg/m^2 for normal weight, overweight and obese, as recommended by the World Health Organization [55] there were 115, 68, 146 individuals in the normal weight, overweight and obese groups, respectively.

Table 3 Distribution of the genotypes, allele's frequencies and odd ratio of the ADRB1 Arg389Gly polymorphism in control, overweight and obese subjects

Genotype	Control T = 115	Overweight T = 68	Obese T = 146	χ2 Odds ratio (95% CI)	P- value
Genotype Frequency					
Arg\Arg	20 (17.4)	12 (17.6)	18 (12.3)	χ2	*P value for Odds ratio in control* vs
Arg\Gly	45 (39.1)	25 (36.8)	57 (39)	Ow = 0.08 Ob = 0.7	*overweight: 0.8 and control* vs *obese:0.4*
Gly\Gly	50 (43.5)	31 (45.6)	71 (48.6)	-Odds ratio (95% CI) Control vs OW 1.09(0.6–1.9) -Odds ratio (95% CI) Control vs Obese 1.2(0.75–1.3)	
Allele Frequency					
Allele Arg389	37.0%	36%	31.8%	*Odds ratio (95% CI) Control* vs *OW*	$P = 0.86$
Allele Gly 389	63.o%	64%	68.2%	1.04 (0.67–1.6) *Odds ratio (95% CI) Control* vs *Obese*1.25(0.9–1.8)	$P = 0.22$

OW = Overweight; Ob = Obese; CI: Confidence interval; χ^2: Chi square

Daghestani *et al. Lipids in Health and Disease* (2018) 17:58

Page 4 of 9

Table 4 Phenotypic characteristics of subjects grouped according to ADRB1 polymorphism at Codon 389

Phenotypic variables	Arg\Arg (n = 50) mean ± SE	Arg\Gly (n = 127) mean ± SE	Gly\Gly (n = 152) mean ± SE	P-value
BMI (kg/m^2)	28.563±1.169	28.500±.64	28.489±.5901	0.998
Waist(cm)	87.84±2.706	88.67±1.640	88.31±1.528	0.964
Hip(cm)	107.24±2.343	108.33±1.34	107.63±1.195	0.888
W/H ratio	.8162±.012	.8160±.009	.8145±.008	0.989
Cholesterol (mmol/L)	3.936±.1241	4.016±.0740	4.043±.0720	0.749
Triglyceride (mmol/L)	1.056±0.0680	.078±0.0459	1.048±0.034	0.865
HDL (mmol/L)	1.1986±0.0441	1.1459±0.0275	1.2084±0.0299	0.292
LDL (mmol/L)	2.072±.111	2.094±0.067	2.122±0.068	0.918
Leptin (ng/ml)	19.57±2.149	23.49±1.67	23.60±1.584	0.383
Fasting Insulin (pmol/L)	79.0±5.68	84.21±3.33	81.09±3.26	0.677
Fasting Glucose(mmol/L)	4.900±0.07	5.002±0.050	4.9±0.043	0.203

Values are mean ± SEM. *Abbreviations*: *BMI*: body mass index; *W/H*: waist hip ratio; High-density lipoproteins; *LDL*: Low-density lipoprotein; *SEM*: Standard Error of the Mean

The anthropometric characteristics of the study subjects are presented in Table 1. All the three groups matched in their age and no statistically significant differences were observed amongst the groups. All other parameters except HDL, were significantly higher in overweight and obese subjects as compared to the normal weight (control) group ($p < 0.0001$) as shown in Table 1. The results of biochemical and hormonal parameters are presented in Table 2 for the three groups. The value for each parameter was elevated significantly, in the overweight and obese subjects, except HDL, which was significantly lower when compared to the normal weight group (Table 2).

Polymorphism in *ADRB1* Arg389Gly genotype

The genotype and allele frequencies of the *ADRB1* Arg389Gly (rs1801253) polymorphism were calculated in each group and results were compared. There was no significant difference in the genotype and allelic frequency of *ADRB1* Arg389Gly between control and obese or overweight subjects, as shown in Table 3. The *ADRB1* genotypes (CC, CG, GG) were grouped separately, and the phenotypic characteristics, biochemical and hormonal parameters were calculated separately for each genotype. No significant differences were observed in the results obtained for the three genotypes (Table 4).

Polymorphism in ADRB3 Trp64Arg genotype

The frequencies of Trp64Arg (rs4994) alleles and genotypes were calculated. The overweight and obese subjects had a significantly higher genotype and allele frequency of Arg64 compared with normal weight subjects. The genotype and allele frequencies in the total group, are presented in Table 5 with the OR, CI, χ^2 and p-value. Furthermore, the study groups were separated according to their Trp64Arg genotypes (TT, TC, CC), and the phenotypic characteristics were obtained. The value of the different parameters in the different genotypes is

Table 5 The genotypes and allele frequencies of ADRB3 Trp64Arg polymorphism in control, overweight and obese subjects

Genotype	Control T = 115	Overweight T = 68	Obese T = 146	χ^2 Odds ratio (95% CI)	P- value
Genotype Frequency					
Trp\Trp	112 (97.4)	61 (89.7)	116 (79.5)	χ^2	P value for Odds ratio in normal vs overweight 0.02 and normal vs obese: 0.0004
Trp\Arg	3 (2.6)	7 (10.3)	23 (15.8)	OW = 4.9 Ob = 12.4	
Arg\Arg	0	0	7 (4.8)	Odds ratio (95% CI) Control vs OW 4.3 (1–17) Odds ratio (95% CI) Control vs Obese 7 (2–24)	
Allele Frequency					
Trp64	98.7%	94.9%	87.3%	Odds ratio (95% CI) Control vs OW 4.11 (1.04–16.1)	P = 0.02
Arg64	1.3%	5.1%	12.7%	Odds ratio (95% CI) Control vs Obese 10.98 (3–36)	P = 0.00001

OW = Overweight; Ob = Obese; CI: Confidence interval; χ^2 = Chi square

Daghestani *et al. Lipids in Health and Disease* (2018) 17:58

Page 5 of 9

Table 6 Phenotypic Characteristics of subjects grouped according to ADRB3 polymorphism at Codon 64

Phenotypic variables	Trp64Trp64 (n = 289) mean ± SE	Trp64Arg64 (n = 33) mean ± SE	Arg64Arg64 (n = 7) mean ± SE	P-value
BMI (kg/m^2)	27.640± 0.402	32.48± 6.36	45.4± 1.8	0.0001
Waist(cm)	86.51± 1.06	98.24± 2.95	119.14 ± 4.83	0.0001
Hip(cm)	106.82± 0.88	112.18± 2.55	129.57± 3.72	0.0001
W/H ratio	0.81 ± 0.01	0.87 ± 0.02	0.92 ± 0.04	0.0001
Cholesterol (mmol/L)	3.94± 0.05	4.36± 0.165	5.63± 0.32	0.0001
Triglyceride (mmol/L)	1.02± 0.03	1.31± 0.09	1.643± 0.181	0.0001
HDL (mmol/L)	1.193 ± 0.02	1.12± 0.05	1.08± 0.120	0.335
LDL (mmol/L)	2.051± 0.045	2.319± 0.147	3.286± 0.244	0.0001
Leptin (ng/ml)	21.95± 1.063	24.38± 2.52	57.14± 10.74	0.0001
Fasting Insulin (pmol/L)	79.018± 2.24	101.6± 6.88	111.70± 17.37	0.001
Fasting Glucose(mmol/L)	4.903± 0.030	5.234± 0.12	4.89± 0.06	0.003

Values are mean ± SEM. *Abbreviations*: *BMI*, body mass index; *W/H*, waist hip ratio

presented in Table 6. This Table shows that the subjects carrying Arg64 in the homozygous state had a greater BMI, waist and hip circumference, W/H ratio, cholesterol, triglyceride, LDL-C, and plasma leptin, insulin, and glucose compared with those with the Trp64Trp and Trp64Arg genotypes, and the difference was significant. However, the decrease in HDL level was not statistically significant (*p*-value = 0.335) in individuals with different ADRB3 genotypes (Table 6).

Table 7 Studies reporting the association of Trp64Arg (rs4994) with obesity and obesity-related disorders in different populations

Population	Study showed rs4994:	References
Asians	Association with T2DM (meta-analysis)	[26]
Non-Asians	No association	
Asians	Association with BMI (meta-analysis)	40
African American	No association with BMI	52
S. African women	No association with MS	41
Brazilians/Caucasians	Combined effect in the modulation of OW/obesity and HDL-C in T2DM	31
Balinese	Association with obesity in rural females only	38
Caucasians	Association with elevated BMI and BMD	48
Chile (Ayara natives)	No association with BMI	50
Chinese	Association with HT and dyslipidaemias (metaanalysis)	27
Hungarian children	Association with increase body weight and BMI	28
S. Italians	Insulin resistance in males only	46
Japanese	Association with increase BMI	51
	No association with BMI	49
	No relation with MS	45
Japanese children	Association with increases visceral fat, blood pressure, triglycerides and reduced TAG	32
Japanese men	Association with annual weight gain	35
Kashmiris	Association with increase BMI, W/H ratio, dyslipidaemias, uncontrolled T2DM	53
Kyrgy	Association with increase obesity, abdominal obesity, decreased HDL	37
Mexican	Association with increase T2DM and MS	39, 29
Russians	Association with increase fat, glucose level, and uric acid	33
S. Spain	Association with T2DM	44
Taiwanese	No association with obesity	36
Saudis	Obesity, hyperlipidaemias, hyperinsulinaemia, hyperleptinaemia.	This study

Daghestani *et al. Lipids in Health and Disease* (2018) 17:58

Page 6 of 9

Discussion

This is the first study to report the relationship between *ADRB1* and *ADRB3* gene polymorphism and obesity-related phenotypes in the Saudi population. Since in our previous report, we had observed an association between Gln27Glu polymorphism of *ADRB2* gene, obesity, and other related disorders in Saudi population [9] our interest was to explore if any association existed between *ADRB1* (rs1801253) and *ADRB3* (rs4994) and these abnormalities. Hence, during this study, a large cohort of 329 subjects was genotyped for Gly389Arg in *ADRB1* (rs1801253) and Trp64Arg in *ADRB3* (rs4994) genes and the association of the variant allele with metabolic parameters were analyzed. The results of our investigation have clearly highlighted the strong association with *ADRB3* polymorphism, where the mutant Arg allele in *ADRB3*, significantly associates with a greater body weight and higher BMI, elevated leptin and dyslipidaemias both in heterozygous and homozygous. It also results in elevated blood glucose level and hyperinsulinaemia. However, the *ADRB1* polymorphism Arg389Gly, shows no association either with the BMI or related disorders. The *ADRB1* is a candidate gene for obesity due to its role in catecholamine mediated energy homeostasis. In 2008, Ohshiro and coworkers had shown a strong association between mutations in the *ADRB1* and massive obesity in Japanese [56]. In obese individuals, the degree of weight loss during a very low calorie diet has been shown to correlate with changes in ADRB1 protein concentration in adipose tissue [57, 58]. An investigation involving a population cohort of 761 women indicated that women carrying the Gly49 genotype had greater elevation in BMI over 15 years compared to those with the Ser49 genotype [59]. Dionne et al., [7] reported that Gly389Arg exhibited a strong relationship with obesity in Caucasian women. In contrast, some studies have reported the Arg389Gly polymorphism had no significant relationship to obesity in Danish [21], Swedish [60] and Japanese [56] subjects, suggesting that it has no role in human obesity. Masuo and Lambert [10] have reviewed various studies about the relationship of polymorphism in either Gly49-Gly389 or Ser49Gly- Arg389Gly in *ADRB1* with obesity or obesity related disorders and have reported contradicting findings among different populations which means that the relationship of *ADRB1* polymorphism to obesity could vary between different populations. In fact, our findings for Arg389 Gly polymorphism in *ADRB1* amongst Saudi population are in line with earlier published reports [7, 21, 61, 62] and suggest that *ADRB1* Arg389Gly polymorphisms do not contribute to obesity and related disorders in the Saudi population.

The *ADRB3* gene is expressed in adipose tissues and stimulates the mobilization of lipids from the WAT and increases thermo-genesis in BAT [10]. Mutation of *ADRB3* in WAT could slow lipolysis and thereby cause the retention of lipids in adipocytes and may contribute to visceral obesity in humans. Interestingly, extensive studies have investigated the role of Trp64Arg (rs4994) in the development of obesity, T2DM, hypertension (HT), cardiovascular disease CAD, dyslipidaemias. Table 7 summarizes some of the studies reported from different populations and shows that there are extensive contradictions between populations, between genders and within different female age groups. Some studies suggest a strong relationship between obesity and Trp64Arg polymorphism in some populations [20, 26–28, 31–33, 35, 37–40, 45, 48, 51, 61–65]. Whereas, other studies on same or different populations have failed to show any association [21, 36, 41, 46, 49, 50, 52]. Even within the same population there are contradictory reports (Table 7). This makes the study of Trp64Arg polymorphism necessary in every population. The present study has found a strong relationship between obesity and Trp64Arg polymorphism in the Saudi population. This is a similar association that we have shown earlier to exist between Gln27Glu polymorphism in *ADRB2* gene and obesity related disorders such as hypertriglyceridemia, hyperinsulinemia, and hyperleptinemia in Saudis [9].

The *ADRB2* and *ARDB3* gene polymorphisms may act as predictive markers for obesity and obesity related disorders in Saudis.

Conclusion

Our present results shows for the first time that obesity and related disorders in Saudis are linked to polymorphism of Trp64Arg (rs4994) in *ADRB3* gene but not to Arg389Gly (rs1801253) in *ARDB1* gene.

Availability of data and materials
All data is available with the authors and can be provided when required.

Daghestani *et al. Lipids in Health and Disease* (2018) 17:58

Page 7 of 9

Authors' contributions

MD[1], ZKH, MHE and AW designed the experiment, carried all the experiments, prepared the tables and drafted the manuscript. MD[2] and MD[3] arranged the subjects/samples of the study. MD and AW drafted of the manuscript. AME, ZKH and MHE participated in the manuscript revision. AME and AW performed all the statistical analysis. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The ethical approval for this study was obtained from the local Institutional Review Board (IRB) at the Umm Al Qura University, Makkah Al Mukaramah, Saudi Arabia (IRB No. 235). Written informed consent was obtained from all study subjects before their participation.

Consent for publication

All authors have read and agreed to the contents of the manuscript and approved the submission.

Competing interests

The authors declare no conflicts of interest, state that the manuscript has not been published or submitted elsewhere, state that the work complies with Ethical Policies of the Journal and the work has been conducted under internationally accepted ethical standards after relevant ethical review.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

[1]Department of Zoology, Center for Scientific and Medical Female Colleges, King Saud University, P.O. Box 22455, Riyadh 11495, Saudi Arabia. [2]Department of Obstetrics and Gynecology, Umm-Al-Qura University, P.O.Box 424, Makkah 21955, Saudi Arabia. [3]Department of Surgery, King Abdulaziz Medical City, National Guard Health Affairs, P.O.Box, Jeddah 9515, Saudi Arabia. [4]Department of Biostatistics, Epidemiology and Scientific Computing, King Faisal Specialist Hospital and Research Center, P.O. Box3354, Riyadh 11211, Saudi Arabia. [5]Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute Cairo University, Cairo, Egypt. [6]Department of Zoology, Faculty of Sciences, King Saud University, P.O. Box 22452, Riyadh 11495, Saudi Arabia. [7]Senior Scientist, Central Laboratory, Center for Scientific and Medical Female Colleges, King Saud University, P.O. Box 22455, Riyadh 11495, Saudi Arabia.

References

1. Warsy AS, El-Hazmi MA. Diabetes mellitus, hypertension and obesity-common multifactorial disorders in Saudis. East Mediterr Health J. 1999;5(6):1236–42. PubMed PMID: 11924118
2. El-Hazmi MA, Warsy AS. Prevalence of overweight and obesity in diabetic and non-diabetic Saudis. East Mediterr Health J. 2000;6(2–3):276–82. PubMed PMID: 11556013
3. Mokdad AH, Bowman BA, Engelgau MM, Vinicor F. The continuing epidemics of obesity and diabetes in the United States. JAMA. 1997;286(10):1195–200.
4. Masuo K, Mikami H, Ogihara T. Tuck ML familial obesity, sympathetic activation and blood pressure level. Blood Press. 2001;10(4):199–204.
5. Cui J, Hopper JL, Harrap SB. Genes and family environment explain correlations between blood pressure and body mass index. Hypertension. 2002;40(1):7–12.
6. Biery AJ, Ebbesson SO, Shuldiner AR, Boyer BB. The beta(3)-adrenergic receptor TRP64ARG polymorphism and obesity in Alaskan Eskimos. Int J Obes Relat Metab Disord. 1997;21(12):1176–9.
7. Dionne IJ, Garant MJ, Nolan AA, Pollin TI, Lewis DG, Shuldiner AR, Poehlman ET. Association between obesity and a polymorphism in the beta(1)-adrenoceptor gene (Gly389Arg ADRB1) in Caucasian women. Int J Obes Relat Metab Disord. 2002;26(5):633–9.
8. Pereira AC, Floriano MS, Mota GF, Cunha RS, Herkenhoff FL, Mill JG, Krieger JE. Beta2 adrenoceptor functional gene variants, obesity, and blood pressure level interactions in the general population. Hypertension. 2003;42(4):685–92.
9. Daghestani MH, Warsy A, Daghestani MH, Al-Odaib AN, Eldali A, Al-Eisa NA, Al-Zahrani S. The Gln27Glu polymorphism in beta2-adrenergic receptor gene is linked to hypertriglyceridemia, hyperinsulinemia and hyperleptinemia in Saudis. Lipids Health Dis. 2010;9:90–5.
10. Masuo K, Lambert GW. Relationships of adrenoceptor polymorphisms with obesity. J Obes. 2011;2011:609485. https://doi.org/10.1155/2011/609485. Epub 2011 Apr 4
11. Skeberdis VA. Structure and function of beta3-adrenergic receptors. Med (Kaunas). 2004;40(5):407–13.
12. Lafontan M, Berlan M. Fat cell adrenergic receptor and the control of white and brown fat cell function. J Lipid Res. 1993;34(7):1057–91.
13. Blaak EE, van Baak MA, Kempen KP, Saris WH. Role of alpha- and beta-adrenoceptors in sympathetically mediated thermogenesis. Am J Phys. 1993;264(1):E11–7.
14. Hagström-Toft E, Enoksson S, Moberg E, Bolinder J, Arner P. Beta-adrenergic regulation of lipolysis and blood flow in human skeletal muscle in vivo. Am J Phys. 1998;275(1):E909–16.
15. Monroe MB, Seals DR, Shapiro LF, Bell C, Johnson D, Parker JP. Direct evidence for tonic sympathetic support of resting metabolic rate in healthy adult humans. Am J Physiol Endocrinol Metab. 2001;280(5):E740–4.
16. Iwashita S, Tanida M, Terui N, Ootsuka Y, Shu M, Kang D, Suzuki M. Direct measurement of renal sympathetic nervous activity in high-fat diet-related hypertensive rats. Life Sci. 2002;71(5):537–46.
17. Enoksson S, Talbot M, Rife F, Tamborlane WV, Shervin RS, Caprio S. Impaired in vivo stimulation of lipolysis in adipose tissue by selective beta2-adrenergic agonist in obese adolescent girls. Diabetes. 2000;49(12):2149–53.
18. Large V, Hellstrom L, Reynisdottir S, Longvist F, Eriksson P, Lannfelt L, Arner P. Human beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adipocyte beta-2 adrenoceptor function. J Clin Invest. 1997;100(12):3005–13.
19. Hellström L, Large V, Reynisdottir S, Wahrenberg H, Arner P. The different effects of a Gln27Glu beta 2-adrenoceptor gene polymorphism on obesity in males and in females. J Intern Med. 1999;245(3):253–9.
20. Masuo K, Katsuya T, Fu Y, Rakugi H, Ogihara T, Tuck ML. Beta2- and beta3-adrenergic receptor polymorphisms are related to the onset of weight gain and blood pressure elevation over 5 years. Circulation. 2005;111(25):3429–34.
21. Gjesing AP, Andersen G, Albrechtsen A, Glümer C, Borch-Johnsen K, Jørgensen T, Hansen T, Pedersen O. Studies of associations between the Arg389Gly polymorphism of the beta1-adrenergic receptor gene (ADRB1) and hypertension and obesity in 7677 Danish white subjects. Diabet Med. 2007;24(4):392–7.
22. Nonen S, Yamamoto I, Liu J, Maeda M, Motomura T, Igarashi T, Fujio Y, Azuma J. Adrenergic beta1 receptor polymorphism (Ser49Gly) is associated with obesity in type II diabetic patients. Biol Pharm Bull. 2008;31(2):295–8.
23. Kim JY, Lee SS. The effects of uncoupling protein 1 and beta3-adrenergic receptor gene polymorphisms on weight loss and lipid profiles in obese women. Int J Vitam Nutr Res. 2010;80(2):87–96.
24. Yamakita M, Ando D, Tang S, Yamagata Z. The Trp64Arg polymorphism of the beta3-adrenergic receptor gene is associated with weight changes in obese Japanese men: a 4-year follow-up study. J Physiol Anthropol. 2010; 29(4):133–9.
25. Ruiz JR, Larrarte E, Margareto J, Ares R, Labayen I. The Arg 389 Gly beta1-adrenergic receptor gene polymorphism and human fat cell lipolysis. Int J Obes Relat Metab Disord. 2011;25(11):1599–603.
26. Ryuk JA, Zhang X, Ko BS, Daily JW, Park S. Association of β3-adrenergic receptor rs4994 polymorphisms with the risk of type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2017;129:86–96. https://doi.org/10.1016/j.diabres.2017.03.034. Epub 2017 May 5. PubMed PMID: 28521197
27. Yang H, Cai D, Zhu Q, Wu D, Wang Q, Wang Z. The mutation of Trp64Arg in β3-adrenoreceptor-encoding gene is significantly associated with increased hypertension risk and elevated blood pressure: a meta-analysis. Oncotarget. 2017; https://doi.org/10.18632/oncotarget.16666. [Epub ahead of print] PubMed PMID:28404887
28. Csernus K, Pauler G, Erhardt É, Lányi É, Molnár D. Effects of energy expenditure gene polymorphisms on obesity-related traits in obese children. Obes Res Clin Pract. 2015;9(2):133–40. https://doi.org/10.1016/j.orcp.2014.06.001. Epub 2014 Jul 8. PubMed PMID: 25081806
29. Burguete-Garcia AI, Martinez-Nava GA, Valladares-Salgado A, Bermudez Morales VH, Estrada-Velasco B, Wacher N, et al. Association of β1 and β3 adrenergic receptors gene polymorphisms with insulin resistance and high

Daghestani *et al. Lipids in Health and Disease* (2018) 17:58

Page 8 of 9

lipid profiles related to type 2 diabetes and metabolic syndrome. Nutr Hosp. 2014;29(6):1327–34. https://doi.org/10.3305/nh.2014.29.6.7367. PubMed PMID: 24972470

30. Kumar S, Mishra A, Srivastava A, Mittal T, Garg N, Mittal B. Significant role of ADRB3 rs4994 towards the development of coronary artery disease. Coron Artery Dis. 2014;25(1):29–34. https://doi.org/10.1097/MCA. 0000000000000056. PubMed PMID:24201118

31. Brondani LA, Duarte GC, Canani LH, Crispim D. The presence of at least three alleles of the ADRB3 Trp64Arg (C/T) and UCP1 -3826A/G polymorphisms is associated with protection to overweight/obesity and with higher high-density lipoprotein cholesterol levels in Caucasian-Brazilian patients with type 2 diabetes. Metab Syndr Relat Disord. 2014; 12(1):16–24. https://doi.org/10.1089/met.2013.0077. Epub 2013 Oct 18. PubMed PMID: 24138564

32. Oguri K, Tachi T, Matsuoka T. Visceral fat accumulation and metabolic syndrome in children: the impact of Trp64Arg polymorphism of the beta3-adrenergic receptor gene. Acta Paediatr. 2013;102(6):613–9. https://doi.org/10.1111/apa.12149. Epub 2013 Jan 22. PubMed PMID: 23282015

33. Baturin AK, Pogozheva AV, Sorokina EI, Makurina ON, Tutel'ian VA. The Trp64Arg polymorphism of beta3-adrenoreceptor gene study in persons with overweight and obesity. Vopr Pitan. 2012;81(2):23–7. PubMed PMID: 22774474

34. Sasayama D, Hori H, Teraishi T, Hattori K, Ota M, Tatsumi M, Higuchi T, Amano N, Kunugi H. Possible impact of ADRB3 Trp64Arg polymorphism on BMI in patients with schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry. 2012;38(2):341–4. https://doi.org/10.1016/j.pnpbp.2012.05.007. Epub 2012 May 17. PubMed PMID: 22609474

35. Takeuchi S, Katoh T, Yamauchi T, Kuroda Y. ADRB3 polymorphism associated with BMI gain in Japanese men. Exp Diabetes Res. 2012:973561. https://doi.org/10.1155/2012/973561. Epub 2012 Apr 8. PubMed PMID: 22550477; PubMed Central.PMCID: PMC3328897

36. Chou YC, Tsai CN, Lee YS, Pei JS. Association of adrenergic receptor gene polymorphisms with adolescent obesity in Taiwan. Pediatr Int. 2012;54(1):111–6. https://doi.org/10.1111/j.1442-200X.2011.03516.x. PubMed PMID: 22115535

37. Mirrakhimov AE, Kerimkulova AS, Lunegova OS, Moldokeeva CB, Zalesskaya YV, Abilova SS, et al. An association betweenTRP64ARG polymorphism of the B3 adreno receptor gene and some metabolic disturbances. Cardiovasc Diabetol. 2011;10:89. https://doi.org/10.1186/1475-2840-10-89. PubMed PMID: 21992420; PubMed Central PMCID: PMC3215178

38. Malik SG, Saraswati MR, Suastika K, Trimarsanto H, Oktavianthi S, Sudoyo H. Association of beta3-adrenergic receptor (ADRB3) Trp64Arg gene polymorphism with obesity and metabolic syndrome in the Balinese: a pilot study. BMC Res Notes. 2011;4:167. https://doi.org/10.1186/1756-0500-4-167. PubMed PMID: 21619577; PubMed Central PMCID: PMC3121622

39. Cruz M, Valladares-Salgado A, Garcia-Mena J, Ross K, Edwards M, Angeles-Martinez J, et al. Candidate gene association study conditioning on individual ancestry in patients with type 2 diabetes and metabolic syndrome from Mexico City. Diabetes Metab Res Rev. 2010;26(4):261–70. https://doi.org/10.1002/dmrr.1082. PubMed PMID: 20503258

40. Kurokawa N, Young EH, Oka Y, Satoh H, Wareham NJ, Sandhu MS, et al. The ADRB3 Trp64Arg variant and BMI: a meta-analysis of 44 833 individuals. Int J Obes. 2008;32(8):1240–9. https://doi.org/10.1038/ijo.2008.90. Epub 2008 Jun 24. Review. PubMed PMID: 18574485

41. Rooyen JM, Pretorius PJ, Britz M, Huisman HW, Schutte AE, Towers GW, et al. Genetic polymorphisms of beta2- and beta3-adrenergic receptor genes associated with characteristics of the metabolic syndrome in black south African women. Exp Clin Endocrinol Diabetes. 2008;116(4):236–40. https://doi.org/10.1055/s-2007-992785. PubMed PMID: 18393130

42. Dunajska K, Lwow F, Milewicz A, Jedrzejuk D, Laczmanski L, Belowska-Bien K, et al. Beta(3)-adrenergic receptor polymorphism and metabolic syndrome in postmenopausal women. Gynecol Endocrinol. 2008;24(3):133–8. https://doi.org/10.1080/09513590801921686. PubMed PMID: 18335327

43. Zafarmand MH, van der Schouw YT, Grobbee DE, de Leeuw PW, Bots ML. T64A polymorphism in beta3-adrenergic receptor gene (ADRB3) and coronary heart disease: a case-cohort study and meta-analysis. J Intern Med. 2008;263(1):79–89. PubMed PMID: 18088254

44. Morcillo S, Cardona F, Rojo-Martínez G, Almaraz MC, Esteva I, Ruiz-De-Adana MS, et al. Effect of the combination of the variants -75G/a APOA1 and Trp64Arg ADRB3 on the risk of type 2 diabetes (DM2). Clin Endocrinol. 2008; 68(1):102–7. Epub 2007 Aug 28. PubMed PMID: 17727676

45. Tamaki S, Nakamura Y, Tabara Y, Okamura T, Kita Y, Kadowaki T, et al. Relationship between metabolic syndrome and Trp64arg polymorphism of the beta-adrenergic receptor gene in a general sample: the Shigaraki study. Hypertens Res. 2006;29(11):891–6. PubMed PMID: 17345789

46. Bracale R, Pasanisi F, Labruna G, Finelli C, Nardelli C, Buono P, et al. Metabolic syndrome and ADRB3 gene polymorphism in severely obese patients from South Italy. Eur J Clin Nutr. 2007;61(10):1213–9. Epub 2007 Feb 14. PubMed PMID: 17299491

47. Wang CY, Nguyen ND, Morrison NA, Eisman JA, Center JR, Nguyen TV. Beta3-adrenergic receptor gene, body mass index, bone mineral density and fracture risk in elderly men and women: the Dubbo osteoporosis epidemiology study (DOES). BMC Med Genet. 2006;7:57. PubMed PMID: 16820065; PubMed Central PMCID: PMC1559683

48. Matsushita Y, Yokoyama T, Yoshiike N, Matsumura Y, Date C, Kawahara K, et al. The Trp(64)Arg polymorphism of the beta(3)-adrenergic receptor gene is not associated with body weight or body mass index in Japanese: a longitudinal analysis. J Clin Endocrinol Metab. 2003;88(12):5914–20.

49. Santos JL, Pérez-Bravo F, Martínez JA, Montalvo D, Albala C, Carrasco E. No evidence for an association between genetic polymorphisms of beta(2)- and beta(3)-adrenergic receptor genes with body mass index in Aymara natives from Chile. Nutrition. 2002;18(3):255–8. PubMed PMID: 11882399

50. Kurokawa N, Nakai K, Kameo S, Liu ZM, Satoh H. Association of BMI with the beta3-adrenergic receptor gene polymorphism in Japanese: meta-analysis. Obes Res. 2001;9(12):741–5. PubMed PMID: 11743057

51. Lowe WL Jr, Rotimi CN, Luke A, Guo X, Zhu X, Comuzzie AG, et al. The beta 3-adrenergic receptor gene and obesity in a population sample of African Americans. Int J Obes Relat Metab Disord. 2001;25(1):54–60. PubMed PMID: 11244458

52. Gagnon J, Mauriège P, Roy S, Sjöström D, Chagnon YC, Dionne FT, et al. The Trp64Arg mutation of the beta3 adrenergic receptor gene has no effect on obesity phenotypes in the Québec family study and Swedish obese subjects cohorts. J Clin Invest. 1996;98(9):2086–93. PubMed PMID: 8903328; PubMed Central PMCID: PMC507653

53. Hameed I, Masoodi SR, Afroze D, Naykoo NA, Bhat RA, Ganai BA. Trp homozygotes at codon 64 of ADRB3 gene are protected against the risk of type 2 diabetes in the Kashmiri population. Genet Test Mol Biomarkers. 2013;17(10):775–9. https://doi.org/10.1089/gtmb.2013.0297. Epub 2013 Aug 22. PubMed PMID: 23968135

54. WHO. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;0:i-xii, 1–253.

55. Ohshiro Y, Hayashi M, Yabiku K, Ueda K, Wakasaki H, Ishigame M, et al. Mutations in the β1 adrenergic receptor gene and massive obesity in Japanese. Diab Res Clin Prac. 2008;80(2):213–7.

56. Rasmussen M, Belza A, Almdal T, Toubro S, Bratholm P, Astrup A, et al. Change in beta1-adrenergic receptor protein concentration in adipose tissue correlates with diet-induced weight loss. Clin Sci (Lond). 2005;108(4):323–9.

57. Masuo K. Roles of Beta2- and Beta3-adrenoceptor polymorphisms in hypertension and metabolic syndrome. Int J Hypertens. 2010:832821. *P*ublished online 2010 Oct 21. doi: https://doi.org/10.4061/2010/832821

58. Linné Y, Dahlman I, Hoffstedt J. beta1-adrenoceptor gene polymorphism predicts long-term changes in body weight. Int J Obes. 2005;29(5):458–62.

59. Rydén M, Hoffstedt J, Eriksson P, Bringman S, Arner P. The Arg 389 Gly beta1-adrenergic receptor gene polymorphism and human fat cell lipolysis. Int J Obes Relat Metab Disord. 2001;25(11):1599–603.

60. Clement K, Vaisse C, Manning BS, Basdevant A, Guy-Grand B, Ruiz J, et al. Genetic variation in the beta 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. N Engl J Med. 1995;333(6):352–4.

61. Sakane N, Yoshida T, Umekawa T, Kogure A, Takakura Y, Kondo M. Effects of Trp64Arg mutation in the beta 3-adrenergic receptor gene on weight loss, body fat distribution, glycemic control, and insulin resistance in obese type 2 diabetic patients. Diabetes Care. 1997;20(12):1887–90.

62. Umekawa T, Yoshida T, Sakane N, Kogure A, Kondo M, Honjyo H. Trp64Arg mutation of beta3-adrenoceptor gene deteriorates lipolysis induced by beta3-adrenoceptor agonist in human omental adipocytes. Diabetes. 1999; 48(1):117–20.

63. Endo K, Yanagi H, Hirano C, Hamaguchi H, Tsuchiya S, Tomura S. Association of Trp64Arg polymorphism of the beta3-adrenergic receptor gene and no association of Gln223Arg polymorphism of the leptin receptor gene in Japanese school children with obesity. Int J Obes Relat Metab Disord. 2002;24(4):443–9.

Daghestani *et al. Lipids in Health and Disease* (2018) 17:58

Page 9 of 9

64. Oizumi T, Daimon M, Saitoh T, Kameda W, Yamaguchi H, Ohnuma H, et al. Funagata diabetes study. Genotype Arg/Arg, but not Trp/Arg, of the Trp64Arg polymorphism of the beta(3)-adrenergic receptor is associated with type 2 diabetes and obesity in a large Japanese sample. Diabetes Care. 2001;24(9):1579–83.

65. Kawaguchi H, Masuo K, Katsuya T, Sugimoto K, Rakugi H, Ogihara T, et al. beta2- and beta3-adrenoceptor polymorphisms relate to subsequent weight gain and blood pressure elevation in obese normotensive individuals. Hypertens Res. 2006;29(12):951–9.